Stuck In Reverse: Another Start-up Takes Reverse Merger Route To Public Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal results in unlikely combination of antbiotics maker Replidyne and device firm Cardiovascular Systems.
You may also be interested in...
Deerfield To NitroMed: Not So Fast, Not So Cheap
NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.
Deerfield To NitroMed: Not So Fast, Not So Cheap
NitroMed stakeholder Deerfield Management moves to block the company’s planned reverse merger with Archemix with a $0.50 per share bid of its own.
Nitromed Reverse Merger Is Quickest Way To Cash For Archemix
Nitromed’s status as essentially a publicly-traded cash shell, with the sell-off of BiDil, made it an attractive partner.